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Genetic risk factors of pancreatic cancer
Carcinoma of the exocrine pancreas is a genetic disease that is caused by inherited and acquired mutations in specific cancer-associated genes. There is no effective screening available and advanced disease is commonly present at initial diagnosis. Established risk factors are cigarette smoking, chronic inflammation of the pancreas, diabetes mellitus and increased body mass. CP and PDAC share common environmental risk factors, such as smoking and heavy alcohol consumption and share some common genetic susceptibility factors as well. Advances in our understanding of the genes involved in the molecular pathogenesis of pancreatic cancer have provided insight into the progression of normal pancreatic ductal cells to noninvasive precursor lesions and to invasive carcinoma; and important implications for the development of chemoprevention and early detection strategies.
Cholecystokinin-B receptor
The gastrin/CCK-B receptor is a member of the G protein-coupled receptor superfamily, 
AIMS
I.
On the basis of its localization in the apical membrane of the pancreatic duct and its function as a Cl -/HCO 3 -exchanger, SLC26A6 has been proposed to be a major contributor to the apical HCO 3 -secretion in the pancreatic duct. However, the role of genetic variations in SLC26A6 has remained unexplored in CP. Therefore we aimed to investigate SLC26A6 gene variants in CP.
Specific aims: in this study, we aimed to sequence the entire coding region of SLC26A6 in 100 non-alcoholic CP cases. We aimed to further investigate the identified variants in
Hungarian and German cohorts of non-alcoholic and alcoholic CP.
II.
There are few known risk factors in pancreatic adenocarcinoma and a better understanding of the molecular pathogenesis is urgently needed. Therefore, we aimed to re-evaluate the role of CCKBR variant c.811+32C>A as a novel genetic prognostic marker.
Specific aims: in this study we had three objectives: (1) to replicate the association between variant c.811+32C>A and the risk for developing pancreatic cancer in an independent population, (2) to evaluate the impact of the variant on patient survival and (3) to examine the functional effect of the variant on pre-mRNA splicing.
PATIENTS AND METHODS OF GENETIC ANALYSIS OF SLC26A6 IN CHRONIC PANCREATITIS Subjects and study design
All patients gave written informed consent for genetic analysis. The study included CP patients originating from Hungary (n = 106) and Germany (n = 361). According to etiology, patients were divided into alcoholic CP and non-alcoholic CP groups. Alcoholic CP was defined by consumption of more than 80g/d (man) ethanol or more than 60g/d (women) for at least two years. 99 Hungarian and 171 German control subjects were recruited from adult volunteers who considered themselves generally healthy.
DNA extraction and genotyping
Genomic DNA was isolated from whole blood. In a discovery cohort of 60 non-alcoholic
Hungarian CP patients the entire coding sequence and adjacent intronic sequences were amplified and sequenced. Primers were designed according to the published sequence of the human SLC26A6 gene (GenBank: NM_022911.2). PCR was performed in a total volume of 30 µl, which contained 0.5 U HotStarTaq DNA Polymerase, 1.5 mM Mg 2 Cl, 0.2 mM dNTP, 0.5 µM primer and 10-50 ng genomic DNA.
Restriction fragment length polymorphism.
Genotyping of the p.V206M and c.1191C>A (p.P397=) variants in the Hungarian cohort was carried out by restriction fragment length polymorphism analysis. PCR was performed with primer sets 7 and 16, and the products were digested with NlaIII and BmrI restriction enzymes, respectively.
Statistical analysis
Quantitative variables were described as mean ± SD. We tested the significance of the differences between allele frequencies in cases and controls by Fisher's exact test and calculated p-values and odds ratios using GraphPad Prism v6.0a.
PATIENTS AND METHODS OF GENETIC ANALYSIS OF CCKBR VARIANT IN PANCREATIC CANCER Study population
All participants gave written informed consent for genetic analysis. 122 cases with a confirmed diagnosis of PDAC were recruited from the Hungarian National Pancreas Registry.
For each patient, information about gender, age at diagnosis, method of diagnosis and date of death or date of last follow-up was collected. 106 control subjects were recruited from adult volunteers who considered themselves generally.
DNA extraction and genotyping
Genomic DNA was isolated from 300 µl EDTA-blood. Primers were designed according to the genomic sequence of CCKBR on chromosome 11 (GenBank NC_000011.10). PCR was performed in a total volume of 30 µl, which contained 0.5 U HotStarTaq DNA Polymerase, 1.5 mM MgCl 2 , 0.2 mM dNTP, 0.5 µM of each primer and 10-50 ng genomic DNA.
Construction of expression plasmids harboring CCKBR minigenes
We designed CCKBR minigenes that contain intron 4 placed in the appropriate context of the full length coding DNA. CCKBR coding DNA (GenBank NM_176875.3) was custom synthesized and cloned into the pcDNA3.1(-) plasmid using XhoI and EcoRI restriction sites.
To create CCKBR minigenes, a 584 nucleotide long fragment containing intron 4 with or without the c.811+32C>A variant was custom synthesized and cloned into the pcDNA3.1(-)
CCKBR plasmid using BsrGI and BamHI restriction sites.
Construction of lentiviral vectors
The pWPI lentivirus vector plasmid and the packaging plasmids (psPAX2 and pMD2.G) were obtained from Didier Trono's laboratory through Addgene. First, CCKBR minigene templates were PCR amplified with Phusion Flash High-Fidelity PCR Master Mix. CCKBR minigene inserts were then subcloned into pWPI plasmid between PmeI and PacI restriction sites. The lentivirus production in HEK 293T packaging cells was performed as described previously.
Viral preparations were titrated on HEK 293T cells.
Cell culture, transfection and viral transduction
Human embrionic kidney (HEK) 293T cells were transfected using 2 µg plasmid DNA and incubation, cells were washed and the transfection medium was replaced with 2 ml DMEM.
Cells were harvested 24 h after this medium change. Capan-1 pancreatic adenocarcinoma cells were transduced with viral supernatant at multiplicity of infections (MOIs) of four.
RNA extraction and reverse transcription
Total RNA was isolated from transfected cells using RNeasy Mini Kit. Two µg RNA was reverse transcribed in the presence of RNase inhibitor RNasin Plus.
Quantification of CCKBR expression and splicing
Real-time PCR reactions were performed with Maxima SYBR Green/ROX qPCR Master Mix (2X) on an ABI PRISM 7000 Sequence Detection System platform. Relative expression was calculated using the comparative CT method (ΔΔCT method). Relative expression of splice variants was studied by using two different primer sets, one amplifying both the spliced and unspliced forms of CCKBR and the other amplifying the intron 4-retaining splice variant (CCKB-Ri4sv) only. For absolute quantification of total CCKBR and CCK-BRi4sv expression, we generated external calibration curves using serial dilutions of minigene plasmid templates.
Using the calibration curves, copy numbers of total CCKBR and unspliced CCK-BRi4sv were determined and expressed as percent of total (spliced plus unspliced) CCKBR expression.
Statistical analysis
Quantitative variables were described as mean ± SE. To test the association between pancreatic cancer and genotype/allele frequencies we used two-tailed Fisher's exact test. Twosided log rank test was used to compare the difference between survival of pancreatic cancer patients harboring the A-allele (A/A or A/C) with survival of those patients with the C/C genotype. All the analyses were performed with GraphPad Prism.
RESULTS OF THE SCL26A6 STUDY
In the Hungarian discovery cohort we included 55 adult and five pediatric patients with nonalcoholic CP. We sequenced 21 exons of SLC26A6. We found four common variants: a missense variant c.616G>A (p.V206M; rs13324142) in exon 6 and three intronic variants:
c.23+71_103del in intron 1 (rs72201074); c. 
RESULTS OF THE CCKBR STUDY Variant c.811+32C>A does not predict risk for PDAC
DISCUSSION
Role of SLC26A6 variants in chronic pancreatitis
Pancreatic ductal HCO 3 -secretion is essential for the maintenance of tissue integrity, and is impaired in CP. In the present study we investigated the association of SLC26A6 variants with CP, based on the crucial role of this candidate gene in the maintenance of ductal fluid and bicarbonate secretion. However, the SLC26A6 variants we identified did not alter the risk for development of either alcoholic or non-alcoholic CP.
Studies on native pancreatic ducts isolated from Slc26a6 -/-mice have been controversial regarding the effect on ductal fluid and bicarbonate secretion. Our group investigated two acute pancreatitis models in Slc26a6 -/-mice, and we did not detect a difference in disease severity compared to the wild type animals (unpublished observations). On the other hand,
Slc26a6
-/-mice exhibit a high incidence of oxalate nephrolithiasis, due to defective intestinal oxalate secretion and urinary excretion. In an attempt to identify association with nephrolithiasis, SLC26A6 variants were screened in familiar hyperoxaluria and primary hyperparathyroidism, but none of the variants increased disease risk. Notably, the authors also reported co-segregation of 3 intronic variations with p.V206M. Functional analysis of the p.V206M mutation in Xenopus oocyte expression studies revealed a 30% decrease of oxalate transport activity. However, the variant did not influence oxalate excretion in heterozygous carrier subjects. Surmising that heterozygosity would result in a 15% reduction in transport, this defect may not be sufficient to alter oxalate homeostasis.
In conclusion, in this study we tested the hypothesis that pancreatitis-associated mutations may be located in the SLC26A6 gene encoding a pancreatic Cl -/HCO 3 -transporter, which interacts with CFTR. We did not find association between genetic variants of SLC26A6 and CP.
Role of CCKBR variant c.811+32C>A in pancreatic cancer
Identification of pancreatic cancer susceptibility genes is of outmost importance to define high-risk populations who may benefit from early detection by screening tests. Based on its role in pancreatic carcinogenesis and regulation of tumor growth CCKBR is a promising candidate for a susceptibility gene. Indeed, several somatic mutations were identified in colorectal and gastric cancers that alter receptor activity, sensitization and localization. Some of these mutations are located in the third intracellular loop of the receptor, which plays a critical role in signal transduction. The same loop is altered by the tumor associated CCKBRi4sv splice variant, which retains intron 4 and codes for an insertion of 69 additional amino acid residues that enhances receptor activity. The molecular basis for this alternative splicing has been explained by aberrant expression of certain auxiliary splicing factors in carcinoma cells that are necessary for the spliceosome assembly. Alternatively, Smith et al. (2012 Smith et al. ( , 2014 proposed that the c.811+32C>A intronic variant in CCKBR can induce retention of intron 4
and thereby increase risk for the development of PDAC and also lead to poorer survival in carriers. In contrast, here we demonstrated that variant c.811+32C>A has no effect on CCKBR mRNA splicing, and it is not associated with increased risk for pancreatic cancer, nor with shorter survival in PDAC.
In conclusion, data presented here argue that intronic variant c.811+32C>A in CCKBR is not associated with PDAC risk or survival in a Hungarian cohort and does not alter splicing of the CCKBR pre-mRNA. Despite the fact that our study was not designed to detect a potentially small effect of variant c.811+32C>A on cancer risk and we did not take into account age and tumor stage at diagnosis when analyzing survival, our findings are convincingly selfconsistent. Therefore, we propose that variant c.811+32C>A is functionally harmless and it should be considered a common polymorphism with no clinical significance. Finally, our results highlight the necessity for replication studies and the importance of functional testing of new genetic risk markers.
SUMMARY
Background: Genetic risk factors are important determinants of disease susceptibility and prognosis in chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma (PDAC). In this thesis two genetic investigations were conducted to gain a deeper comprehension of the pathophysiology of these diseases.
I.
Pancreatic ductal HCO 3 -secretion is critically dependent on the cystic fibrosis transmembrane conductance regulator chloride channel (CFTR) and the solute-linked carrier 26 member 6 anion transporter (SLC26A6). Deterioration of HCO 3 -secretion is observed in CP, and CFTR mutations increase CP risk. Therefore, SLC26A6 is a reasonable candidate for a CP susceptibility gene, which has not been investigated in CP patients so far.
II.
Single nucleotide polymorphism c.811+32C>A in intron 4 of the cholecystokinin-B receptor gene (CCKBR) was previously reported to correlate with higher PDAC risk and poorer survival. The variant was suggested to induce retention of intron 4, resulting in a new spliceform with enhanced receptor activity. Our objective was to validate the c.811+32C>A
variant as an emerging biomarker for pancreatic cancer risk and prognosis.
Patients and methods
I.
As a first screening cohort, 106 subjects with CP and 99 control subjects with no pancreatic disease were recruited from the Hungarian National Pancreas Registry. In 60 nonalcoholic CP cases the entire SLC26A6 coding region was sequenced. In the Hungarian cohort variants c.616G>A (p.V206M) and c.1191C>A (p.P397=) were further genotyped by restriction fragment length polymorphism analysis. In a German replication cohort all exons were sequenced in 40 non-alcoholic CP cases and variant c.616G>A (p.V206M) was further analyzed by sequencing in 321 CP cases and 171 controls.
II.
We genotyped variant c.811+32C>A in 122 PDAC cases and 106 controls by sequencing and examined its association with cancer risk and patient survival. To test the functional effect of variant c.811+32C>A on pre-mRNA splicing, we transfected HEK 293T cells and Capan-1 cells with CCKBR minigenes.
Results
I.
Sequencing of the entire coding region revealed four common variants: intronic 
II.
The allele frequency of the variant was similar between patients and controls (17.9%
and 18.4%, respectively). Survival analysis showed no significant difference between median survival of patients with the C/C genotype (266 days) and patients with the A/C or A/A genotypes (257 days). CCKBR minigenes with or without variant c.811+32C>A exhibited no difference in expression of the intron-retaining splice variant.
Conclusion
I.
Our data show that SLC26A6 variants do not alter the risk for the development of CP.
II:
These data indicate that variant c.811+32C>A in CCKBR does not have a significant impact on pancreatic cancer risk or survival.
